Charles River Laboratories International, Inc. (CRL)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Charles River Laboratories International, Inc. (CRL) is down 9.0% since the beginning of the year. At $182 per share, CRL is trading 20.7% below its 52-week high of $229. Investors who bought $1,000 worth of CRL shares 5 years ago would now be looking at an investment worth $495.

Charles River Laboratories International, Inc. (CRL) has returned -8.98% so far this year and 23.13% over the past 12 months. Over the last ten years, CRL has returned 8.49% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.

Based on dividend-adjusted daily data since Jun 23, 2000, CRL's average daily return is +0.06%, while the average monthly return is +1.19%. At this rate, an investment would double in approximately 4.9 years.

Historically, 57% of months were positive and 43% were negative. The best month was Jul 2000 with a return of +36.1%, while the worst month was Nov 2008 at -36.4%. The longest winning streak lasted 14 consecutive months, and the longest losing streak was 6 months.

On a daily basis, CRL closed higher 52% of trading days. The best single day was May 7, 2025 with a return of +18.7%, while the worst single day was Apr 10, 2025 at -28.1%.

Charles River Laboratories International, Inc. has an annualized alpha of 8.31%, beta of 0.87, and R2 of 0.22 versus S&P 500 Index. Calculated based on daily prices since June 23, 2000.

• This stock captured 121.47% of S&P 500 Index gains and 108.03% of its losses - amplifying both gains and losses, but participating more in upside than downside.
• R2 of 0.22 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

CRL ranks 57 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Charles River Laboratories International, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Charles River Laboratories International, Inc. was 78.23%, occurring on Apr 11, 2025. The portfolio has not yet recovered.

The current Charles River Laboratories International, Inc. drawdown is 60.38%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Charles River Laboratories International, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Charles River Laboratories International, Inc. is priced in the market compared to other companies in the Diagnostics & Research industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.